FINASTHMA cost study is a retrospective, register-based study aiming to characterize the economic burden of oral corticosteroid (OCS) use in asthma by utilizing Finnish nationwide data. The study will provide novel information on the cost landscape related to OCS use and common OCS use-associated comorbidities in the Finnish asthma population, and whether the costs can be reduced by biologic treatments.
